Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bellerophon Therapeutics stock | $3.8

Learn how to easily invest in Bellerophon Therapeutics stock.

Bellerophon Therapeutics Inc is a biotechnology business based in the US. Bellerophon Therapeutics shares (BLPH) are listed on the NASDAQ and all prices are listed in US Dollars. Bellerophon Therapeutics employs 21 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Bellerophon Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BLPH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Bellerophon Therapeutics stock price (NASDAQ: BLPH)

Use our graph to track the performance of BLPH stocks over time.

Bellerophon Therapeutics shares at a glance

Information last updated 2021-10-23.
Latest market close$3.80
52-week range$3.66 - $9.75
50-day moving average $3.95
200-day moving average $4.26
Wall St. target price$25.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.61

Buy Bellerophon Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
$0
0%
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bellerophon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bellerophon Therapeutics price performance over time

Historical closes compared with the close of $3.8 from 2021-10-26

1 week (2021-10-17) N/A
1 month (2021-09-28) -6.17%
3 months (2021-07-28) -15.37%
6 months (2021-04-28) -15.37%
1 year (2020-10-27) -53.94%
2 years (2019-10-25) 763.64%
3 years (2018-10-26) 375.00%
5 years (2016-10-27) 204.00%

Bellerophon Therapeutics financials

Gross profit TTM $0
Return on assets TTM -27.97%
Return on equity TTM -59.37%
Profit margin 0%
Book value $3.17
Market capitalisation $36.5 million

TTM: trailing 12 months

Shorting Bellerophon Therapeutics shares

There are currently 54,503 Bellerophon Therapeutics shares held short by investors – that's known as Bellerophon Therapeutics's "short interest". This figure is 2.8% down from 56,086 last month.

There are a few different ways that this level of interest in shorting Bellerophon Therapeutics shares can be evaluated.

Bellerophon Therapeutics's "short interest ratio" (SIR)

Bellerophon Therapeutics's "short interest ratio" (SIR) is the quantity of Bellerophon Therapeutics shares currently shorted divided by the average quantity of Bellerophon Therapeutics shares traded daily (recently around 31144.571428571). Bellerophon Therapeutics's SIR currently stands at 1.75. In other words for every 100,000 Bellerophon Therapeutics shares traded daily on the market, roughly 1750 shares are currently held short.

However Bellerophon Therapeutics's short interest can also be evaluated against the total number of Bellerophon Therapeutics shares, or, against the total number of tradable Bellerophon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bellerophon Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Bellerophon Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0069% of the tradable shares (for every 100,000 tradable Bellerophon Therapeutics shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bellerophon Therapeutics.

Find out more about how you can short Bellerophon Therapeutics stock.

Bellerophon Therapeutics share dividends

We're not expecting Bellerophon Therapeutics to pay a dividend over the next 12 months.

Have Bellerophon Therapeutics's shares ever split?

Bellerophon Therapeutics's shares were split on a 1:15 basis on 9 February 2020. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellerophon Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Bellerophon Therapeutics shares which in turn could have impacted Bellerophon Therapeutics's share price.

Bellerophon Therapeutics share price volatility

Over the last 12 months, Bellerophon Therapeutics's shares have ranged in value from as little as $3.66 up to $9.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bellerophon Therapeutics's is -0.5042. This would suggest that Bellerophon Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Bellerophon Therapeutics has bucked the trend.

Bellerophon Therapeutics overview

Bellerophon Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc.

Frequently asked questions

What percentage of Bellerophon Therapeutics is owned by insiders or institutions?
Currently 4.045% of Bellerophon Therapeutics shares are held by insiders and 32.904% by institutions.
How many people work for Bellerophon Therapeutics?
Latest data suggests 21 work at Bellerophon Therapeutics.
When does the fiscal year end for Bellerophon Therapeutics?
Bellerophon Therapeutics's fiscal year ends in December.
Where is Bellerophon Therapeutics based?
Bellerophon Therapeutics's address is: 184 Liberty Corner Road, Warren, NJ, United States, 07059
What is Bellerophon Therapeutics's ISIN number?
Bellerophon Therapeutics's international securities identification number is: US0787713009
What is Bellerophon Therapeutics's CUSIP number?
Bellerophon Therapeutics's Committee on Uniform Securities Identification Procedures number is: 078771102

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site